Last reviewed · How we verify
ENDOXAN
ENDOXAN (cyclophosphamide) is an alkylating agent that cross-links DNA to inhibit cell division and induce apoptosis in rapidly dividing cells.
ENDOXAN (cyclophosphamide) is an alkylating agent that cross-links DNA to inhibit cell division and induce apoptosis in rapidly dividing cells. Used for Lymphomas (Hodgkin and non-Hodgkin), Leukemias, Multiple myeloma.
At a glance
| Generic name | ENDOXAN |
|---|---|
| Also known as | cyclophosphamide, Cyclophosphamide |
| Sponsor | Celyad Oncology SA |
| Drug class | Alkylating agent |
| Target | DNA (non-specific alkylation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is a nitrogen mustard alkylating agent that requires hepatic activation to form active metabolites. These metabolites covalently bind to DNA, creating inter- and intra-strand cross-links that prevent DNA replication and transcription, leading to cell cycle arrest and apoptosis. It is used both as a cytotoxic chemotherapy agent and as an immunosuppressant due to its effects on lymphocyte proliferation.
Approved indications
- Lymphomas (Hodgkin and non-Hodgkin)
- Leukemias
- Multiple myeloma
- Breast cancer
- Ovarian cancer
- Autoimmune diseases (lupus nephritis, vasculitis)
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Hemorrhagic cystitis
- Infertility
- Secondary malignancies
- Immunosuppression/infection risk
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENDOXAN CI brief — competitive landscape report
- ENDOXAN updates RSS · CI watch RSS
- Celyad Oncology SA portfolio CI